Latigo Biotherapeutics is a private clinical-stage biotechnology company developing innovative non-opioid pain medicines with potential best-in-class profiles that directly target the source of pain. Latigo's goal is to provide effective, rapid-acting pain relief without the risk of addiction.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/17/25 | $150,000,000 | Series B |
5AM Ventures Access Biotechnology Alexandria Venture Investments Blue Owl  Cormorant Asset Management Deep Track Capital Foresite Capital Kern Capital Qatar Investment Authority Rock Springs Capital Sanofi Ventures UPMC Enterprises Westlake Village BioPartners | undisclosed |
